Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
NRSNW
Upturn stock ratingUpturn stock rating

NeuroSense Therapeutics Ltd. Warrant (NRSNW)

Upturn stock ratingUpturn stock rating
$0.63
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: NRSNW (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $0

1 Year Target Price $0

Analysts Price Target For last 52 week
$0Target price
Low$
Current$0.63
high$

Analysis of Past Performance

Type Stock
Historic Profit -81.58%
Avg. Invested days 30
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size ETF
Market Capitalization 0 USD
Price to earnings Ratio -
1Y Target Price -
Price to earnings Ratio -
1Y Target Price -
Volume (30-day avg) -
Beta 1.6
52 Weeks Range 0.10 - 1.06
Updated Date 06/21/2025
52 Weeks Range 0.10 - 1.06
Updated Date 06/21/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.94

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -159.5%
Return on Equity (TTM) -2478.16%

Valuation

Trailing PE -
Forward PE -
Enterprise Value -
Price to Sales(TTM) -
Enterprise Value -
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -
Shares Outstanding -
Shares Floating 11925007
Shares Outstanding -
Shares Floating 11925007
Percent Insiders -
Percent Institutions -

Analyst Ratings

Rating -
Target Price -
Buy -
Strong Buy -
Buy -
Strong Buy -
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

NeuroSense Therapeutics Ltd. Warrant

stock logo

Company Overview

overview logo History and Background

NeuroSense Therapeutics Ltd. is a biotechnology company focused on discovering and developing treatments for neurodegenerative diseases. The warrants give the holder the right to purchase common stock at a specified price and date.

business area logo Core Business Areas

  • Drug Development: Research and development of therapeutics targeting neurodegenerative diseases like ALS and Alzheimer's. Their main focus is on developing small molecule drugs to treat these conditions.

leadership logo Leadership and Structure

The leadership team consists of experienced professionals in drug development and biotechnology management. The organizational structure likely includes research, development, and clinical trial departments.

Top Products and Market Share

overview logo Key Offerings

  • PrimeC: PrimeC is NeuroSense's leading drug candidate for ALS. Currently undergoing clinical trials. While specific market share data is unavailable due to its developmental stage, potential competitors include Mitsubishi Tanabe Pharma (Radicava) and Amylyx Pharmaceuticals (Relyvrio).

Market Dynamics

industry overview logo Industry Overview

The neurodegenerative disease market is large and growing due to the aging global population. It is characterized by high unmet needs and intense competition.

Positioning

NeuroSense is a smaller player in a market dominated by larger pharmaceutical companies. They are focused on developing novel therapies.

Total Addressable Market (TAM)

The total addressable market for neurodegenerative disease treatments is estimated to be in the tens of billions of dollars. NeuroSense is positioning itself to capture a portion of this market with its pipeline of drug candidates.

Upturn SWOT Analysis

Strengths

  • Novel drug candidates targeting unmet needs
  • Experienced leadership team
  • Strong intellectual property portfolio

Weaknesses

  • Limited financial resources compared to larger competitors
  • Dependence on clinical trial success
  • Single product focus

Opportunities

  • Partnerships with larger pharmaceutical companies
  • Positive clinical trial results
  • Expansion into new indications

Threats

  • Clinical trial failures
  • Competition from established therapies
  • Regulatory hurdles
  • Funding challenges

Competitors and Market Share

competitor logo Key Competitors

  • AMTX
  • ABBV
  • BMY

Competitive Landscape

NeuroSense is a small biotech company competing with larger, more established pharmaceutical companies. Their advantage lies in their novel drug candidates and focus on specific neurodegenerative diseases. The main disadvantages are the reliance on clinical trial success and fund-raising.

Growth Trajectory and Initiatives

Historical Growth: Growth is tied to preclinical and clinical development milestones rather than revenue growth.

Future Projections: Future growth is dependent on the successful development and commercialization of PrimeC and other drug candidates.

Recent Initiatives: Recent initiatives include advancing PrimeC through clinical trials and exploring new indications.

Summary

NeuroSense Therapeutics is a clinical-stage biotech firm focused on neurodegenerative disease treatments, primarily PrimeC for ALS. Its strength lies in novel drug development, but it faces weaknesses like limited resources and reliance on clinical trial outcomes. Opportunities exist in partnerships and new indications. Investors should watch out for clinical trial results and funding challenges.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Website
  • SEC Filings
  • Analyst Reports
  • Industry Publications

Disclaimers:

This analysis is for informational purposes only and should not be considered investment advice. The data provided is based on publicly available information and may not be entirely accurate or complete. Investing in warrants, particularly in early-stage biotech companies, carries significant risk.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About NeuroSense Therapeutics Ltd. Warrant

Exchange NASDAQ
Headquaters -
IPO Launch date 2021-12-09
Co-Founder, CEO & Director Mr. Alon Ben-Noon
Sector Healthcare
Industry Biotechnology
Full time employees 17
Full time employees 17

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.